CoChat

Choosing anticancer drug targets in the postgenomic era

Open access
Kaelin, William G. · 1999 · Journal of Clinical Investigation
Cited by 79

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The human genome project will be completed in the early part of the next decade.For example, most of the approximately 10 5 human mRNAs have already been at least partially cloned and sequenced as cDNAs.These cDNAs, when completed, will provide valuable tools for studying the protein products of their respective mRNAs.The challenge in the postgenomic era will be to apply advances in molecular oncology to select from among this diverse set of proteins the most suitable candidates for anti-cancer drug discovery programs.Here, I outline some considerations that may be helpful in choosing rational drug targets for cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci8888

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 79

Metadata

Authors
Kaelin, W. G.
Venue
Journal of Clinical Investigation
Published
1999-12-01
Volume
104
Issue
11
Pages
1503-1506
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2033371646
Cited by
79
References
3
FWCI
3.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Choosing anticancer drug targets in the postgenomic era. https://app.cochat.ai/papers/10.1172/jci8888
The paper
Kaelin, W. G. (1999). Choosing anticancer drug targets in the postgenomic era. Journal of Clinical Investigation. https://doi.org/10.1172/jci8888

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.